BTIG Reiterates Buy Rating for Ascentage Pharma Group
BTIG maintains a positive outlook on Ascentage Pharma Group with a reiterated buy rating and a $48 price target.
Key Points
- BTIG reiterated its buy rating on Ascentage Pharma Group with a price target of $48 on June 16, 2026.
- Ascentage Pharma Group, trading at $17.34, has a market cap of $1.62 billion and a 52-week range from $16.92 to $48.45.
- Analysts are optimistic about AAPG, with a consensus strong buy rating and a target mean price of $47.56.
On June 16, 2026, BTIG reiterated its buy rating on Ascentage Pharma Group Internat (NasdaqGM: AAPG), setting a price target of $48. This affirmation comes as the stock is trading at $17.34.
Analysts Set New Price Targets
BTIG's analyst Jeet Mukherjee reaffirmed the buy rating for Ascentage Pharma with a $48 target. On June 10, 2026, B. Riley Securities initiated coverage with a buy rating and a $45 target. Earlier in the year, on March 12, BTIG also assumed coverage with a buy rating and a similar $48 target. The consensus among analysts is a strong buy, with a target mean price of $47.56 based on nine opinions.
Ascentage Pharma Group Stock Snapshot
Shares of Ascentage Pharma Group Internat are currently trading at $17.34. The company, with a market cap of approximately $1.62 billion, operates in the biotechnology sector. It has a forward P/E ratio of -14.51, indicating it is not currently profitable. The stock's 52-week range spans from $16.92 to $48.45, with a 50-day moving average of $21.81 and a 200-day moving average of $28.21. Ascentage Pharma has a current ratio of 1.79 and a quick ratio of 1.69, with a debt-to-equity ratio of 148.38.
About Ascentage Pharma Group Internat
Ascentage Pharma Group International is a biotechnology company based in Suzhou, China. It focuses on developing therapies for cancer, chronic hepatitis B, and age-related diseases. The company's key products include HQP1351 for targeting BCR-ABL1 mutants, APG-2575 for hematologic malignancies, and APG-115 for solid tumors and hematological malignancies. Ascentage Pharma collaborates with various biotechnology and pharmaceutical companies to advance its research and development efforts.
Bottom Line
BTIG's reaffirmation of a buy rating and a $48 target price underscores continued confidence in Ascentage Pharma Group's potential. Ascentage Pharma remains a focal point for investors interested in the biotechnology sector, with analysts maintaining a strong buy consensus. While 13F filings offer a historical snapshot, the analyst ratings provide a forward-looking perspective on the company's prospects.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.